State Street’s Elicio Therapeutics ELTX Stock Holding History

State Street’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$702K	Buy	179,420 +128,800	+254%	+$1.29M	﹤0.01%	3514
2026 Q1	$541K	Buy	50,620 +4,320	+9%	+$41.7K	﹤0.01%	3637
2025 Q4	$369K	Buy	46,300 +8,000	+21%	+$72.6K	﹤0.01%	3758
2025 Q3	$419K	Buy	38,300 +16,700	+77%	+$169K	﹤0.01%	3699
2025 Q2	$167K	Hold	21,600	–	–	﹤0.01%	3880
2025 Q1	$133K	Sell	21,600 -300	-1%	-$2.32K	﹤0.01%	3910
2024 Q4	$107K	Hold	21,900	–	–	﹤0.01%	3973
2024 Q3	$110K	Hold	21,900	–	–	﹤0.01%	3960
2024 Q2	$90K	Buy	21,900 +4,300	+24%	+$36.4K	﹤0.01%	4035
2024 Q1	$134K	Buy	+17,600	New	+$88.2K	﹤0.01%	3969
2023 Q2	–	Sell	-1,270	Closed	-$7.37K	–	4690
2023 Q1	$7.37K	Hold	1,270	–	–	﹤0.01%	4757
2022 Q4	$10.3K	Hold	1,270	–	–	﹤0.01%	4804
2022 Q3	$12K	Sell	1,270 -300	-19%	-$3.13K	﹤0.01%	4882
2022 Q2	$18K	Sell	1,570 -18,979	-92%	-$303K	﹤0.01%	4883
2022 Q1	$436K	Sell	20,549 -2,122	-9%	-$47.9K	﹤0.01%	4110
2021 Q4	$657K	Buy	22,671 +6,684	+42%	+$338K	﹤0.01%	3918
2021 Q3	$1.56M	Buy	15,987 +7,446	+87%	+$804K	﹤0.01%	3679
2021 Q2	$1.11M	Buy	8,541 +3,840	+82%	+$554K	﹤0.01%	3645
2021 Q1	$849K	Buy	+4,701	New	+$907K	﹤0.01%	3658

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street's ELTX Position: Q2 2026 in Review

State Street increased its Elicio Therapeutics (ELTX) stake by 254% in Q2 2026, buying an estimated $1.29M and bringing the position to 179,420 shares worth $702K. The position accounts for ﹤0.01% of the portfolio, ranked #3514.

State Street first reported a position in ELTX in Q1 2021 and has held it in 19 quarters since. The position peaked at $1.56M in Q3 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

State Street held 179,420 shares of Elicio Therapeutics worth $702K as of Q2 2026.
State Street bought 128,800 Elicio Therapeutics shares in Q2 2026, an estimated $1.29M.
Elicio Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3514 holding.
State Street first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 19 quarters since.
State Street's Elicio Therapeutics position peaked at $1.56M in Q3 2021.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.